Acromegaly Market 2027

DelveInsight's 'Acromegaly - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Acromegaly in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acromegaly from 2016 to 2027 segmented by seven major markets. The Report also covers the current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Acromegaly- Disease Understanding and Treatment Algorithm

The DelveInsight Acromegaly market report gives the thorough understanding of the Acromegaly by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acromegaly in the US, Europe, and Japan.

Acromegaly Epidemiology

The Acromegaly epidemiology division provides the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, origin-based cases, diagnosed cases, diagnosed cases based on type of adenomas and treatable cases) scenario of Acromegaly in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to DelveInsight, the total number of prevalent population of Acromegaly was found to be 60,610, in the year 2016.

Acromegaly Drug Chapters

This segment of the Acromegaly report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Present medical therapies available to treat Acromegaly consist of Somatostatin Analogues (SSAs) and Dopamine Agonist (DA) medication, both of which act to suppress GH secretion from pituitary adenomas or remnant tissue and thus lead to reduced IGF-1 levels and reduced symptoms. The GH receptor antagonist Pegvisomant is helpful in patients who are resistant or partially respondent to Somatostatin Analogs. Seven therapies, five Somatostatin Analogs, and two Growth Hormone Receptor Antagonists are expected to enter the 7MM Acromegaly market by 2027. Detailed chapter of Somatostatin Analogs (Octreotide capsules, Lanreotide PRF, Veldoreotide, CAM2029, GT-02037), and Growth hormone receptor antagonists (IONIS-GHR-LRx, ATL1103)) have been covered in the report.

Acromegaly Market Outlook

The Acromegaly market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Acromegaly in 7MM was found to be USD 848.0 million in 2016 and is expected to increase at a CAGR of XX% from 2016-2027.

Acromegaly Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acromegaly Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acromegaly Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Acromegaly Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Acromegaly market
  • Organize sales and marketing efforts by identifying the best opportunities for Acromegaly market
  • To understand the future market competition in the Acromegaly market.

1. Key Insights

2. Acromegaly Market Overview at a Glance

2.1. Market (%) Distribution of Acromegaly in 2017

2.2. Market (%) Distribution of Acromegaly in 2027

3. Disease Overview: Acromegaly (ACM)

3.1. Introduction

3.2. Signs and Symptoms

3.3. Classification of Pituitary Adenomas

3.4. Clinical Manifestations of Acromegaly

3.5. Etiology

3.6. Pathophysiology

3.7. Genetic bases of acromegaly

3.8. Pathogenesis

3.9. Diagnosis

3.9.1. Diagnosis guidelines

3.9.2. Endocrine Society Clinical Practice Guideline-United Kingdom

3.9.3. American Association of Clinical Endocrinologists (AACE) - U.S.A.

4. Epidemiology and Patient Population

5. Key Findings

6. 7MM Epidemiology

6.1. Total Prevalent Cases of Acromegaly in 7MM

6.2. Origin Based Cases of Acromegaly in 7MM

7. United States Epidemiology

7.1. Total Prevalent Cases of Acromegaly in the United States

7.2. Origin-Based Cases of Acromegaly in the United States

7.3. Diagnosed Cases of Acromegaly in the United States

7.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in the United States

7.5. Treatable Cases of Acromegaly in the United States

8. EU5 Epidemiology

8.1. United Kingdom

8.1.1. Total Prevalent Cases of Acromegaly in the United Kingdom

8.1.2. Origin-Based Cases of Acromegaly in the United Kingdom

8.1.3. Diagnosed Cases of Acromegaly in the United Kingdom

8.1.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in the United Kingdom

8.1.5. Treatable Cases of Acromegaly in the United Kingdom

8.2. Germany

8.2.1. Total Prevalent Cases of Acromegaly in Germany

8.2.2. Origin-Based Cases of Acromegaly in Germany

8.2.3. Diagnosed Cases of Acromegaly in Germany

8.2.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in Germany

8.2.5. Treatable Cases of Acromegaly in Germany

8.3. France

8.3.1. Total Prevalent Cases of Acromegaly in France

8.3.2. Origin Based Cases of Acromegaly in France

8.3.3. Diagnosed Cases of Acromegaly in France

8.3.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in France

8.3.5. Treatable Cases of Acromegaly in France

8.4. Italy

8.4.1. Total Prevalent Cases of Acromegaly in Italy

8.4.2. Origin-Based Cases of Acromegaly in Italy

8.4.3. Diagnosed Cases of Acromegaly in Italy

8.4.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in Italy

8.4.5. Treatable Cases of Acromegaly in Italy

8.5. Spain

8.5.1. Total Prevalent Cases of Acromegaly in Spain

8.5.2. Origin-Based Cases of Acromegaly in Spain

8.5.3. Diagnosed Cases of Acromegaly in Spain

8.5.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in Spain

8.5.5. Treatable Cases of Acromegaly in Spain

9. Japan Epidemiology

9.1. Total Prevalent Cases of Acromegaly in Japan

9.2. Origin-Based Cases of Acromegaly in Japan

9.3. Diagnosed Cases of Acromegaly in Japan

9.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in Japan

9.5. Treatable Cases of Acromegaly in Japan

10. Treatment

10.1. Biomarkers of Acromegaly

10.2. Treatment Guidelines

10.2.1. American Association of Clinical Endocrinologists (AACE) - U.S.A.

10.2.2. Endocrine Society Clinical Practice Guideline-United Kingdom

11. Unmet Needs

12. Marketed Drug

12.1. Somatuline Depot (lanreotide acetate): Ipsen Biopharmaceuticals

12.1.1. Drug Description

12.1.2. Mechanism of Action

12.1.3. Regulatory Milestones

12.1.4. Advantages & Disadvantages

12.1.5. Safety and Efficacy

12.1.6. Product Profile

12.2. Somavert (pegvisomant): Pharmacia & Upjohn

12.2.1. Drug Description

12.2.2. Mechanism of Action

12.2.3. Regulatory Milestones

12.2.4. Advantages & Disadvantages

12.2.5. Safety and Efficacy

12.2.6. Product Profile

12.3. Sandostatin LAR Depot: Novartis Pharmaceuticals

12.3.1. Drug Description

12.3.2. Mechanism of Action

12.3.3. Regulatory Milestones

12.3.4. Advantages & Disadvantages

12.3.5. Safety and Efficacy

12.3.6. Product Profile

12.4. Signifor LAR (pasireotide): Novartis Pharmaceuticals

12.4.1. Drug Description

12.4.2. Mechanism of Action

12.4.3. Regulatory Milestones

12.4.4. Advantages & Disadvantages

12.4.5. Safety and Efficacy

12.4.6. Product Profile

13. Key Cross Competitors

14. Emerging Drugs

14.1. IONIS-GHR-LRx: Ionis Pharmaceuticals

14.1.1. Product Description

14.1.2. Other Developmental Activities

14.1.3. Clinical Development

14.1.4. Clinical Trials Information

14.1.5. Safety and Efficacy

14.1.6. Product Profile

14.2. Octreotide capsules: Chiasma Pharma

14.2.1. Product Description

14.2.2. Other Developmental Activities

14.2.3. Clinical Development

14.2.4. Clinical Trials Information

14.2.5. Safety and Efficacy

14.2.6. Product Profile

14.3. ATL1103: Antisense Therapeutics

14.3.1. Product Description

14.3.2. Other Developmental Activities

14.3.3. Clinical Development

14.3.4. Clinical Trials Information

14.3.5. Safety and Efficacy

14.3.6. Product Profile

14.4. CAM2029: Novartis

14.4.1. Product Description

14.4.2. Other Developmental Activities

14.4.3. Clinical Development

14.4.4. Clinical Trials Information

14.4.5. Safety and Efficacy

14.4.6. Advantages and Disadvantages

14.4.7. Product Profile

14.5. GT-02037: Pharmaspur

14.5.1. Product Description

14.5.2. Clinical Development

14.5.3. Clinical Trials Information

14.5.4. Product Profile

14.6. Veldoreotide: Evotec/ Aspireo Pharmaceuticals

14.6.1. Product Description

14.6.2. Other Developmental Activities

14.6.3. Clinical Development

14.6.4. Clinical Trials Information

14.6.5. Safety and Efficacy

14.6.6. Advantages and Disadvantages

14.6.7. Product Profile

15. Acromegaly: 7Major Market Analysis

15.1. Key Findings

15.2. Market Size of Acromegaly in 7MM

16. The United States: Market Outlook

16.1. The United States Market Size

16.2. Total Market size of Acromegaly

16.3. Market Size by Therapies

17. EU5: Market Outlook

17.1. The United Kingdom Market Size

17.1.1. Total Market size of Acromegaly

17.1.2. Market Size by Therapies

17.2. Germany Market Size

17.2.1. Total Market size of Acromegaly

17.2.2. Market Size by Therapies

17.3. France Market Size

17.3.1. Total Market size of Acromegaly

17.3.2. Market Size by Therapies

17.4. Italy Market Size

17.4.1. Total Market size of Acromegaly

17.4.2. Market Size by Therapies

17.5. Spain Market Size

17.5.1. Total Market size of Acromegaly

17.5.2. Market Size by Therapies

18. Japan: Market Outlook

18.1. Japan Market Size

18.1.1. Total Market size of WM

18.1.2. Market Size by Therapies

19. Market Drivers

20. Market Barriers

21. Appendix

21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Table 1: The 2017 WHO Pathological Classification of Pituitary adenomas

Table 2: Mutated genes associated with acromegaly/gigantism

Table 3: Genes that contribute to the molecular pathogenesis of GH-secreting adenomas

Table 4: Total Prevalent Cases of Acromegaly in 7MM (2016-2027)

Table 5: Origin Based Cases of Acromegaly in 7MM (2016-2027)

Table 6: Total Prevalent Cases of Acromegaly in the US (2016-2027)

Table 7: Origin Based Cases of Acromegaly in the US (2016-2027)

Table 8: Diagnosed Cases of Acromegaly in the US (2016-2027)

Table 9: Diagnosed Cases of Acromegaly Based on Types of Adenomas in the US (2016-2027)

Table 10: Treatable Cases of Acromegaly in the US (2016-2027)

Table 11: Total Prevalent Cases of Acromegaly in the UK (2016-2027)

Table 12: Origin Based Cases of Acromegaly in the UK (2016-2027)

Table 13: Diagnosed Cases of Acromegaly in the UK (2016-2027)

Table 14: Diagnosed Cases of Acromegaly Based on Types of Adenomas in the UK (2016-2027)

Table 15: Treatable Cases of Acromegaly in the UK (2016-2027)

Table 16: Total Prevalent Cases of Acromegaly in Germany (2016-2027)

Table 17: Origin Based Cases of Acromegaly in Germany (2016-2027)

Table 18: Diagnosed Cases of Acromegaly in Germany (2016-2027)

Table 19: Diagnosed Cases of Acromegaly Based on Types of Adenomas in Germany (2016-2027)

Table 20: Treatable Cases of Acromegaly in Germany (2016-2027)

Table 21: Total Prevalent Cases of Acromegaly in France (2016-2027)

Table 22: Origin Based Cases of Acromegaly in France (2016-2027)

Table 23: Diagnosed Cases of Acromegaly in France (2016-2027)

Table 24: Diagnosed Cases of Acromegaly Based on Types of Adenomas in France (2016-2027)

Table 25: Treatable Cases of Acromegaly in France (2016-2027)

Table 26: Total Prevalent Cases of Acromegaly in Italy (2016-2027)

Table 27: Origin Based Cases of Acromegaly in Italy (2016-2027)

Table 28: Diagnosed Cases of Acromegaly in Italy (2016-2027)

Table 29: Diagnosed Cases of Acromegaly Based on Types of Adenomas in Italy (2016-2027)

Table 30: Treatable Cases of Acromegaly in Italy (2016-2027)

Table 31: Total Prevalent Cases of Acromegaly in Spain (2016-2027)

Table 32: Origin Based Cases of Acromegaly in Spain (2016-2027)

Table 33: Diagnosed Cases of Acromegaly in Spain (2016-2027)

Table 34: Diagnosed Cases of Acromegaly Based on Types of Adenomas in Spain (2016-2027)

Table 35: Treatable Cases of Acromegaly in Spain (2016-2027)

Table 36: Total Prevalent Cases of Acromegaly in Japan (2016-2027)

Table 37: Origin Based Cases of Acromegaly in Japan (2016-2027)

Table 38: Diagnosed Cases of Acromegaly in Japan (2016-2027)

Table 39: Diagnosed Cases of Acromegaly Based on Types of Adenomas in Japan (2016-2027)

Table 40: Treatable Cases of Acromegaly in Japan (2016-2027)

Table 41: IONIS-GHR-LRx, Clinical Trial Description, 2018

Table 42: Octreotide capsules, Clinical Trial Description, 2018

Table 43: ATL1103,Clinical Trial Description, 2018

Table 44: CAM2029,Clinical Trial Description, 2018

Table 45: GT-02037,Clinical Trial Description, 2018

Table 46: DG3173,Clinical Trial Description, 2018

Table 47: 7 Major Market Size of Acromegaly in USD Million (2016-2027)

Table 48: Market Size of Acromegaly in the United States, USD Millions (2016-2027)

Table 49: Therapy Based Market Size of Acromegaly in the United States, USD Million (2016-2027)

Table 50: Market Size of Acromegaly in the United Kingdom, USD Millions (2016-2027)

Table 51: Therapy Based Market Size of Acromegaly in the United Kingdom, USD Million (2016-2027)

Table 52: Market Size of Acromegaly in Germany, USD Millions (2016-2027)

Table 53: Therapy Based Market Size of Acromegaly in Germany, USD Million (2016-2027)

Table 54: Market Size of Acromegaly in France, USD Millions (2016-2027)

Table 55: Therapy Based Market Size of Acromegaly in France, USD Million (2016-2027)

Table 56: Market Size of WM in Italy, USD Millions (2016-2027)

Table 57: Therapy Based Market Size of Acromegaly in Italy, USD Million (2016-2027)

Table 58: Market Size of Acromegaly in Spain, USD Millions (2016-2027)

Table 59: Therapy Based Market Size of Acromegaly in Spain, USD Million (2016-2027)

Table 60: Market Size of Acromegaly in Japan, USD Millions (2016-2027)

Table 61: Therapy Based Market Size of Acromegaly in Japan, USD Million (2016-2027)

Figure 1: Change in facial features in Acromegaly

Figure 2: Clinical Manifestations of Acromegaly

Figure 3: Clinical Features of Acromegaly

Figure 4: Etiology of Acromegaly

Figure 5: Pathophysiology of Acromegaly

Figure 6: Molecular Pathogenesis of Acromegaly

Figure 7: Normal and disrupted the GHRH-GH-IGF1 axis and molecular targets for therapy.

Figure 8: Diagnostic Algorithm of Acromegaly

Figure 9: Total Prevalent cases of Acromegaly in 7MM (2016-2027)

Figure 10: Origin Based Cases of Acromegaly in 7MM (2016-2027)

Figure 11: Total Prevalent cases of Acromegaly in the US (2016-2027)

Figure 12: Origin Based Cases of Acromegaly in the US (2016-2027)

Figure 13: Diagnosed Cases of Acromegaly in the US (2016-2027)

Figure 14: Diagnosed Cases of Acromegaly Based on Types of Adenomas in the US (2016-2027)

Figure 15: Treatable Cases of Acromegaly in the US (2016-2027)

Figure 16: Total Prevalent cases of Acromegaly in the UK (2016-2027)

Figure 17: Origin Based Cases of Acromegaly in the UK (2016-2027)

Figure 18: Diagnosed Cases of Acromegaly in the UK (2016-2027)

Figure 19: Diagnosed Cases of Acromegaly Based on Types of Adenomas in the UK (2016-2027)

Figure 20: Treatable Cases of Acromegaly in the UK (2016-2027)

Figure 21: Total Prevalent cases of Acromegaly in Germany (2016-2027)

Figure 22: Origin Based Cases of Acromegaly in Germany (2016-2027)

Figure 23: Diagnosed Cases of Acromegaly in Germany (2016-2027)

Figure 24: Diagnosed Cases of Acromegaly Based on Types of Adenomas in Germany (2016-2027)

Figure 25: Treatable Cases of Acromegaly in Germany (2016-2027)

Figure 26: Total Prevalent cases of Acromegaly in France (2016-2027)

Figure 27: Origin Based Cases of Acromegaly in France (2016-2027)

Figure 28: Diagnosed Cases of Acromegaly in France (2016-2027)

Figure 29: Diagnosed Cases of Acromegaly Based on Types of Adenomas in France (2016-2027)

Figure 30: Treatable Cases of Acromegaly in France (2016-2027)

Figure 31: Total Prevalent cases of Acromegaly in Italy (2016-2027)

Figure 32: Origin Based Cases of Acromegaly in Italy (2016-2027)

Figure 33: Diagnosed Cases of Acromegaly in Italy (2016-2027)

Figure 34: Diagnosed Cases of Acromegaly Based on Types of Adenomas in Italy (2016-2027)

Figure 35: Treatable Cases of Acromegaly in Italy (2016-2027)

Figure 36: Total Prevalent cases of Acromegaly in Spain (2016-2027)

Figure 37: Origin Based Cases of Acromegaly in Spain (2016-2027)

Figure 38: Diagnosed Cases of Acromegaly in Spain (2016-2027)

Figure 39: Diagnosed Cases of Acromegaly Based on Types of Adenomas in Spain (2016-2027)

Figure 40: Treatable Cases of Acromegaly in Spain (2016-2027)

Figure 41: Total Prevalent cases of Acromegaly in Japan (2016-2027)

Figure 42: Origin Based Cases of Acromegaly in Japan (2016-2027)

Figure 43: Diagnosed Cases of Acromegaly in Japan (2016-2027)

Figure 44: Diagnosed Cases of Acromegaly Based on Types of Adenomas in Japan (2016-2027)

Figure 45: Treatable Cases of Acromegaly in Japan (2016-2027)

Figure 46: Treatment therapies for Acromegaly

Figure 47: Treatment Algorithm

Figure 48: Clinical Features of Acromegaly

Figure 49: Unmet needs for Acromegaly

Figure 50: 7 Major Market Size of Acromegaly in USD Million (2016-2027)

Figure 51: Market Size of Acromegaly in the United States, USD Millions (2016-2027)

Figure 52: Therapies Based market of Acromegaly in the United States, USD Million (2016-2027)

Figure 53: Market Size of Acromegaly in the United Kingdom, USD Millions (2016-2027)

Figure 54: Therapies Based market of Acromegaly in the United Kingdom, USD Million (2016-2027)

Figure 55: Market Size of Acromegaly in Germany, USD Millions (2016-2027)

Figure 56: Therapies Based market of Acromegaly in Germany, USD Million (2016-2027)

Figure 57: Market Size of Acromegaly in France, USD Millions (2016-2027)

Figure 58: Therapies Based market of Acromegaly in France, USD Million (2016-2027)

Figure 59: Market Size of Acromegaly in Italy, USD Millions (2016-2027)

Figure 60: Therapies Based market of Acromegaly in Italy, USD Million (2016-2027)

Figure 61: Market Size of Acromegaly in Spain, USD Millions (2016-2027)

Figure 62: Therapies Based market of Acromegaly in Spain, USD Million (2016-2027)

Figure 63: Market Size of Acromegaly in Japan, USD Millions (2016-2027)

Figure 64:Therapies Based market of Acromegaly in Japan, USD Million (2016-2027)

Figure 65: Market Drivers

Figure 66:Market Barriers

  • Tags:
  • Acromegaly market
  • Acromegaly market research
  • Acromegaly market insight
  • Acromegaly market trends
  • Acromegaly market forecast
  • Acromegaly market share
  • Acromegaly pipeline drugs
  • Acromegaly treatment algorithm
  • Acromegaly drugs
  • Acromegaly sales forecasting
  • Acromegaly market size
  • Acromegaly disease
  • Acromegaly epidemiology
  • Acromegaly
  • Acromegaly Companies
  • Acromegaly Pipeline

Forward to Friend

Need A Quote